0 CHECKOUT

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

  • ID: 3502767
  • October 2015
  • 203 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Absynth Biologics Limited
  • AvidBiotics Corp.
  • Immuron Limited
  • Microbiotix, Inc.
  • Oragenics, Inc.
  • Sanofi Pasteur SA
  • MORE

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

Summary

The report ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015’, provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Absynth Biologics Limited
  • AvidBiotics Corp.
  • Immuron Limited
  • Microbiotix, Inc.
  • Oragenics, Inc.
  • Sanofi Pasteur SA
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview

Therapeutics Development

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Overview

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Development by Companies

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Development by Companies

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Investigation by Universities/Institutes

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Companies Involved in Therapeutics Development

Absynth Biologics Limited

Actelion Ltd

Adenium Biotech ApS

AIMM Therapeutics B.V.

Akthelia pharmaceuticals ehf

AmpliPhi Biosciences Corporation

Angothera GmbH

Assembly Biosciences, Inc.

AvidBiotics Corp.

C3 Jian, Inc

Daiichi Sankyo Company, Limited

Evec, Inc.

GangaGen Inc.

ImmunoBiology Limited

Immuron Limited

Inovio Pharmaceuticals, Inc.

Intrexon Corporation

MedImmune, LLC

Merck & Co., Inc.

MGB Biopharma Limited

Microbiotix, Inc.

Micropharm Limited

Morphochem AG

Nanotherapeutics, Inc.

Novabiotics Limited

NovoBiotic Pharmaceuticals, LLC

Oragenics, Inc.

Pfizer Inc.

Procarta Biosystems Ltd

Prokarium Limited

Rebiotix Inc.

Sanofi Pasteur SA

Sarum Biosciences Limited

Sequella, Inc.

Seres Therapeutics, Inc.

Shire Plc

Sorrento Therapeutics, Inc.

Stellar Biotechnologies, Inc.

Summit Therapeutics Plc

Synthetic Biologics, Inc.

Valevia UK Limited

Valneva SE

VaxInnate Corporation

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(actoxumab + bezlotoxumab) - Drug Profile

ABCD-01 - Drug Profile

actoxumab - Drug Profile

AKT-10081 - Drug Profile

Antibodies for Enterocolitis - Drug Profile

AP-114 - Drug Profile

AvR2-V10 - Drug Profile

bezlotoxumab - Drug Profile

Biologic for Clostridium Difficile Enteropathy - Drug Profile

Biologic for Clostridium difficile Infections - Drug Profile

C-3CD17 - Drug Profile

cadazolid - Drug Profile

Cdiff snare - Drug Profile

clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

clostridium difficile vaccine - Drug Profile

CRS-3123 - Drug Profile

Drug for Clostridium difficile Infection - Drug Profile

Endolysin - Drug Profile

EV-029104 - Drug Profile

EV-029105A - Drug Profile

fidaxomicin - Drug Profile

GBV-006 - Drug Profile

IMM-529 - Drug Profile

INS-001 - Drug Profile

INX-201 - Drug Profile

MB-101 - Drug Profile

MBX-500 - Drug Profile

MCB-3681 - Drug Profile

MGBBP-3 - Drug Profile

Monoclonal Antibodies for Clostridium difficile - Drug Profile

Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile

Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile

MU-1140 - Drug Profile

NP-432 - Drug Profile

OraCAb - Drug Profile

P-2-A - Drug Profile

P-4A - Drug Profile

PF-06425090 - Drug Profile

PolyCAb - Drug Profile

PRO-391 - Drug Profile

ramoplanin - Drug Profile

RBX-2660 - Drug Profile

ridinilazole - Drug Profile

SER-109 - Drug Profile

SER-262 - Drug Profile

Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile

Small Molecules for Clostridium Difficile Infections - Drug Profile

Small Molecules for Clostridium Difficile Infections - Drug Profile

Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile

Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile

SMT-21829 - Drug Profile

SQ-109 - Drug Profile

SQ-641 - Drug Profile

surotomycin - Drug Profile

SYN-004 - Drug Profile

VAL-301 - Drug Profile

VLA-84 - Drug Profile

VP-20621 - Drug Profile

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Recent Pipeline Updates

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Akthelia pharmaceuticals ehf, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Evec, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Immuron Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Intrexon Corporation, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Morphochem AG, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Procarta Biosystems Ltd, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sarum Biosciences Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sequella, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Shire Plc, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valneva SE, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by VaxInnate Corporation, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Routes of Administration, H2 2015

Number of Products by Stage and Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
Akthelia pharmaceuticals ehf
AmpliPhi Biosciences Corporation
Angothera GmbH
Assembly Biosciences, Inc.
AvidBiotics Corp.
C3 Jian, Inc
Daiichi Sankyo Company, Limited
Evec, Inc.
GangaGen Inc.
ImmunoBiology Limited
Immuron Limited
Inovio Pharmaceuticals, Inc.
Intrexon Corporation
MedImmune, LLC
Merck & Co., Inc.
MGB Biopharma Limited
Microbiotix, Inc.
Micropharm Limited
Morphochem AG
Nanotherapeutics, Inc.
Novabiotics Limited
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Pfizer Inc.
Procarta Biosystems Ltd
Prokarium Limited
Rebiotix Inc.
Sanofi Pasteur SA
Sarum Biosciences Limited
Sequella, Inc.
Seres Therapeutics, Inc.
Shire Plc
Sorrento Therapeutics, Inc.
Stellar Biotechnologies, Inc.
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Valevia UK Limited
Valneva SE
VaxInnate Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.